Filing search / Kineta, Inc. / "Injured"

8-K

EX-99.5

KANT Kineta, Inc.

22 Dec 22

Kineta Completes Reverse Merger with Yumanity Therapeutics

5:02pm

product candidates. Such events could subject Kineta to costly litigation, require Kineta to pay substantial amounts of money to injured patients

8-K

EX-99.6

KANT Kineta, Inc.

22 Dec 22

Kineta Completes Reverse Merger with Yumanity Therapeutics

5:02pm

is liable to provide ‘no fault’ compensation to any study subject injured in the clinical trial. Prior to commencing a clinical trial, the sponsor

424B3

KANT Kineta, Inc.

10 Nov 22

Prospectus supplement

4:21pm

substantial amounts of money to injured patients, delay, negatively impact or end Kineta’s opportunity to receive or maintain regulatory approval

8-K

EX-10.1

mn7q5ezfkhe0zl1fp

4 Mar 22

Entry into a Material Definitive Agreement

4:15pm

S-4

EX-10.18

dpn53gh 2y00k

23 Sep 20

Registration of securities issued in business combination transactions

4:50pm